We evaluated the therapeutic potential of Runx1‐based MMT targeted therapy on lung cancer by daily injection of Runx1 specific inhibitor Ro5‐3335 (5 mg kg−1 i.p.)into immunocompetent mice bearing syngeneic lung cancer LLC. This evidence concerns the gene RUNX1 and lung carcinoma.